Confirm delete?

Bertin Bioreagent
logo
All categories
Contact Us
You are here :

sPLA2 (Type V) Inhibitor Screening Assay Kit

  • Zoom
    sPLA<sub>2</sub> (Type V) Inhibitor Screening Assay Kit
  • sPLA<sub>2</sub> (Type V) Inhibitor Screening Assay Kit
Cat No: 10004883
Assay Kits - Colorimetric Assays
Cayman
€513.00
Price is excluding VAT and does not include packaging neither shipping

Phospholipase A2 (PLA2) catalyzes the hydrolysis of phospholipids at the sn-2 position yielding a free fatty acid and a lysophospholipid. The release of arachidonic acid from membrane phospholipids by PLA2 is believed to be a key step in the control of...

More
: 96 wells

This product can only be bought through Cayman Chemical. Please contact us.

- +
Territorial Availability: Available through Bertin Technologies only in Europe
Technical Warning: Check the Additional Items Required section of this kit booklet to verify if UltraPure Water (Milli-Q or equivalent) is needed for this assay
Correlated keywords:
  • assays measures kits inhibition inhibitors phospholipases inflammation eicosanoids colorimetric sPLA2s enzymes diheptanoyl thio-pc
Product Overview:
Phospholipase A2 (PLA2) catalyzes the hydrolysis of phospholipids at the sn-2 position yielding a free fatty acid and a lysophospholipid. The release of arachidonic acid from membrane phospholipids by PLA2 is believed to be a key step in the control of eicosanoid production within the cell.{1474} Mammalian tissues contain many secretory PLA2s (sPLA2s), including types IB, IIA-F, III, V, X, and XII{3506} of which Type V sPLA2 is involved in eicosanoid formation in inflammatory cells, such as macrophages and mast cells.{4455,11782} It has been demonstrated that human type V sPLA2 can bind phosphatidylcholine (PC) membranes and hydrolyze PC substrates much more efficiently than human type IIA sPLA2, which makes it better suited for acting on the outer plasma membrane.{8384} Selective targeting and inhibition of sPLA2s has been problematic as evidenced by the lack of availability of isozyme-specific inhibitors. The Cayman Chemical sPLA2 (Type V) Inhibitor Screening Assay is a convenient colorimetric assay designed for rapid screening of Type V sPLA2 inhibitors in a 96 well format. The sPLA2 (Type V) Inhibitor Screening assay kit includes sufficient human recombinant Type V sPLA2 for a minimum of 100 reactions. Identification of selective sPLA2 inhibitors will offer substantial aid in the elucidation of the specific physiological function of each sPLA2. Each kit contains assay buffer, DTNB, diheptanoyl thio-PC, human sPLA2, a 96 well plate, plate cover, and complete instructions.
Size 96 wells
Shipping dry ice
Stability Store at -20 degrees; shelf life 365 days
Custom Code 3822.00
UNSPSC code 41116104

Dennis, E.A. Diversity of group types, regulation, and function of phospholipase A2. J Biol Chem 269 13057-13060 (1994).

Han, S., Yoon, E.T., and Cho, W. Bacterial expression and characterization of human secretory class V phospholipase A2

Cayman Chemical's mission is to help make research possible by supplying scientists worldwide with the basic research tools necessary for advancing human and animal health. Our utmost commitment to healthcare researchers is to offer the highest quality products with an affordable pricing policy.

Our scientists are experts in the synthesis, purification, and characterization of biochemicals ranging from small drug-like heterocycles to complex biolipids, fatty acids, and many others. We are also highly skilled in all aspects of assay and antibody development, protein expression, crystallization, and structure determination.

Over the past thirty years, Cayman developed a deep knowledge base in lipid biochemistry, including research involving the arachidonic acid cascade, inositol phosphates, and cannabinoids. This knowledge enabled the production of reagents of exceptional quality for cancer, oxidative injury, epigenetics, neuroscience, inflammation, metabolism, and many additional lines of research.

Our organic and analytical chemists specialize in the rapid development of manufacturing processes and analytical methods to carry out clinical and commercial GMP-API production. Pre-clinical drug discovery efforts are currently underway in the areas of bone restoration and repair, muscular dystrophy, oncology, and inflammation. A separate group of Ph.D.-level scientists are dedicated to offering Hit-to-Lead Discovery and Profiling Services for epigenetic targets. Our knowledgeable chemists can be contracted to perform complete sample analysis for analytes measured by the majority of our assays. We also offer a wide range of analytical services using LC-MS/MS, HPLC, GC, and many other techniques.

Accreditations
ISO/IEC 17025:2005
ISO Guide 34:2009

Cayman is a leader in the field of emerging drugs of abuse, providing high-purity Schedule I-V Controlled Substances to federally-licensed laboratories and qualified academic research institutions for forensic analyses. We are certified by ACLASS Accreditation Services with dual accreditation to ISO/IEC 17025:2005 and ISO Guide 34:2009.

/ We also advise you

Cross selling for this product : sPLA<sub>2</sub> (Type V) Inhibitor Screening Assay Kit There are 10 products.

Search